 Polygenic risk scores, PRS, have been shown to capture part of an individual's susceptibility to complex diseases that their clinical utility has yet to be established. PRS may be used to estimate an individual's lifetime genetic risk of disease, but the current discriminative ability is low in the general population. Clinical implementation of PRS may be useful in cohorts with a higher prior probability of disease, such as early stages of diseases for diagnosis or treatment choices. However, there are challenges in translating an individual's PRS from a percentile of a normal distribution to a lifetime disease risk and a weaker evidence base in application to non-European ancestry. This article was authored by Catherine M. Lewis and Yvonne Lospassos.